Study highlights benefit of mRNA boosters for SARS-CoV-2 following different initial vaccine types

A study by researchers from the United Kingdom finds no difference in the protection offered by mRNA vaccine boosters against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) when comparing those that have received BioNTech/Pfizer vaccine as a primary course to those that have received Oxford/AstraZeneca. The paper is currently available on the medRxiv*

Continue Reading

News Source:

Leave a comment